Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 350 participants.
Also called NCT07527078
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 350 participants
- Sponsor
- Registry
-
NCT07527078
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07527078. Randomized; no masking; primary purpose treatment. Start 2026-04-07 (actual); primary completion 2026-04-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes (T2DM)
- Intervention (Drug)
- GZR33 Injection
- Intervention (Drug)
- Insulin Degludec Injection (Tresiba®)
- Lead sponsor
- Gan & Lee Pharmaceuticals.
Record details
- Record id
cardio:ct-nct07527078- Content hash
823b6cd473cd8f83bddc4ba551bf756d559ab8399c9169ce570bf0cb33e6729e